Arisan Therapeutics Inc.
Carlsbad, CA
- UEI
- PYRKTQPNVJZ8
- CAGE
- 616D2
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5825 Avenida Encinas #101, Carlsbad, CA 92008, USA
- Website
- arisanthera.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $2,933,547 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $3,692,037 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $2,933,547 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Arisan Therapeutics Inc. is a corporate entity providing research and development services to U.S. federal agencies, primarily the Department of Health and Human Services and the Department of Defense. Through federal contracts, the company conducts non-clinical toxicology studies and provides research services associated with developing countermeasures against chemical and biological threats.
Arisan Therapeutics has been awarded over $5 million in federal contracts from HHS and DOD agencies since 2020. This includes a $3.7 million definitive contract from the National Institutes of Health to perform reproductive toxicology and Good Laboratory Practice toxicology studies. Additionally, Arisan was awarded a $1.1 million Phase II SBIR contract to conduct research and development supporting the Joint Program Executive Office for Chemical and Biological Defense. The company has also received Phase I and Phase II SBIR contracts from this DOD agency totaling over $790,000 to serve as a principal investigator and conduct pharmacokinetic and tolerability studies. The SBIR awards have been designated as total small business set asides.
Through a project grant from the NIH National Institute of Allergy and Infectious Diseases, Arisan Therapeutics was provided $7.1 million to complete IND-enabling and advanced nonclinical studies for a preclinical candidate oral entry inhibitor drug with demonstrated broad spectrum antiviral efficacy against arenaviruses. The project aims to develop a treatment for Lassa virus and other viral hemorrhagic fevers.
Quick answers
Is Arisan Therapeutics Inc. registered in SAM.gov?
Yes. Arisan Therapeutics Inc.'s SAM.gov registration is active through December 18, 2026.
What is Arisan Therapeutics Inc.'s CAGE code?
Arisan Therapeutics Inc.'s CAGE code is 616D2, and its Unique Entity ID (UEI) is PYRKTQPNVJZ8.
How much has Arisan Therapeutics Inc. received in federal contracts?
Federal contracts obligated $6,625,584 to Arisan Therapeutics Inc. in fiscal years 2023 through 2027.
What is Arisan Therapeutics Inc.'s most recent federal award?
Arisan Therapeutics Inc.'s most recent federal contract award is To develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection (75N93026C00012), from National Institute of Allergy and Infectious Diseases (NIH), on August 3, 2026.
On GovTribe
See Arisan Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors